Clinically, a large number of studies reveal that KIF2A shows the potential of a biomarker for several kinds of cancers: a high KIF2A expression is associated with more lymph node metastasis, advanced tumor stage, and/or shortened overall survival (OS) in patients with cervical, colorectal, lung, TSCC, nasopharyngeal cancers, and so on (12, 17, 18, 20, 23). Here, KIF2A is linked to cancer.